TY - JOUR
T1 - GMPPB-congenital disorders of glycosylation associate with decreased enzymatic activity of GMPPB
AU - Liu, Zhe
AU - Wang, Yan
AU - Yang, Fan
AU - Yang, Qin
AU - Mo, Xianming
AU - Burstein, Ezra
AU - Jia, Da
AU - Cai, Xiao tang
AU - Tu, Yingfeng
N1 - Funding Information:
This research is supported by Natural Science Foundation of China (NSFC) grants (#91854121, #31871429, #81901281), National Key Research and Development Program of China (2018YFC1005004), and Sichuan Science and Technology Program (2018RZ0128).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - The congenital disorders of glycosylation (CDG) are a family of metabolic diseases in which glycosylation of proteins or lipids is deficient. GDP-mannose pyrophosphorylase B (GMPPB) mutations lead to CDG, characterized by neurological and muscular defects. However, the genotype-phenotype correlation remains elusive, limiting our understanding of the underlying mechanism and development of therapeutic strategy. Here, we report a case of an individual presenting congenital muscular dystrophy with cerebellar involvement, who presents two heterozygous GMPPB mutations (V111G and G214S). The V111G mutation significantly decreases GMPPB’s enzymatic activity. By measuring enzymatic activities of 17 reported GMPPB mutants identified in patients diagnosed with GMPPB-CDG, we discover that all tested GMPPB variants exhibit significantly decreased enzymatic activity. Using a zebrafish model, we find that Gmppb is required for neuronal and muscle development, and further demonstrate that enzymatic activity of GMPPB mutants correlates with muscular and neuronal phenotypes in zebrafish. Taken together, our findings discover the importance of GMPPB enzymatic activity for the pathogenesis of GMPPB-CDG, and shed light for the development of additional indicators and therapeutic strategy.
AB - The congenital disorders of glycosylation (CDG) are a family of metabolic diseases in which glycosylation of proteins or lipids is deficient. GDP-mannose pyrophosphorylase B (GMPPB) mutations lead to CDG, characterized by neurological and muscular defects. However, the genotype-phenotype correlation remains elusive, limiting our understanding of the underlying mechanism and development of therapeutic strategy. Here, we report a case of an individual presenting congenital muscular dystrophy with cerebellar involvement, who presents two heterozygous GMPPB mutations (V111G and G214S). The V111G mutation significantly decreases GMPPB’s enzymatic activity. By measuring enzymatic activities of 17 reported GMPPB mutants identified in patients diagnosed with GMPPB-CDG, we discover that all tested GMPPB variants exhibit significantly decreased enzymatic activity. Using a zebrafish model, we find that Gmppb is required for neuronal and muscle development, and further demonstrate that enzymatic activity of GMPPB mutants correlates with muscular and neuronal phenotypes in zebrafish. Taken together, our findings discover the importance of GMPPB enzymatic activity for the pathogenesis of GMPPB-CDG, and shed light for the development of additional indicators and therapeutic strategy.
KW - Congenital disorders of glycosylation
KW - Enzymatic activity
KW - GMPPB
KW - Zebrafish model
UR - http://www.scopus.com/inward/record.url?scp=85118468568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118468568&partnerID=8YFLogxK
U2 - 10.1186/s43556-021-00027-2
DO - 10.1186/s43556-021-00027-2
M3 - Article
C2 - 35006422
AN - SCOPUS:85118468568
SN - 2662-8651
VL - 2
JO - Molecular Biomedicine
JF - Molecular Biomedicine
IS - 1
M1 - 13
ER -